BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Epilepsy and seizures clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for epilepsy: 91 (52 sponsors; 11 newly posted in the last 180 days, 6 stopped in the last 180 days; 5 new-entrant sponsors). Momentum score 17, rank 36 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 1, Phase 1 7, Phase 2 24, Phase 3 29, Phase 4 4, N/A 26.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Praxis Precision Medicines PRAX7P2 2, P3 503
Xenon Pharmaceuticals Inc. XENE4P3 3, P2 101
Longboard Pharmaceuticals3P3 301
Jazz Pharmaceuticals JAZZ5P3 2, P4 2, NA 131
Biohaven Therapeutics Ltd. BHVN4P2 1, P3 2, P1 102
Rapport Therapeutics Inc. RAPP4P2 1, P1 1, P3 210
Ono Pharmaceutical Co., Ltd.3P3 2, P2 102
UCB Biopharma SRL3P3 2, NA 100
Epygenix2P3 201
Neurona Therapeutics2P2 1, P3 100
SK Life Science, Inc.2P4 1, P3 101
Stoke Therapeutics, Inc STOK2P3 1, P2 101
Immedica Pharma AB1P3 100
Oils4Cure1P3 100
Zogenix, Inc.1P3 100
Encoded Therapeutics3P2 300
Supernus Pharmaceuticals, Inc. SUPN3P2 300
Actio Biosciences, Inc.2P1 1, P2 112
Epiminder America, Inc.2NA 200
NaviFUS Corporation2NA 1, P2 101
Neuronostics Ltd2NA 200
NeuroPace NPCE2NA 1, P2 112
Shanghai Zhimeng Biopharma, Inc.2P2 200
Adraxe Corp. new entrant1EARLY_P1 110
Aeovian Pharmaceuticals, Inc. new entrant1P2 110

New-entrant sponsors: Adraxe Corp., Aeovian Pharmaceuticals, Inc..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P2NeuroPace NPCENCT05339126 RNS System LGS Feasibility StudyEpilepsy; Lennox Gastaut Syndrome; Lennox-Gastaut Syndrome, Intractable; Seizures; Seizures, Generalactive not recruiting24
2026-11-30 est.P1/P2UniQure Biopharma B.V. QURENCT06063850 AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe EpilepsyMesial Temporal Lobe Epilepsyrecruiting12
2026-12 est.P2/P3Biohaven Therapeutics Ltd. BHVNNCT06132893 A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyFocal Epilepsyactive not recruiting390
2026-12 est.P2Biohaven Therapeutics Ltd. BHVNNCT06443463 Long-term Safety and Tolerability of BHV-7000Focal Epilepsyenrolling by invitation660
2026-12 est.P3Praxis Precision Medicines PRAXNCT07010471 A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of RelutrigineDevelopmental and Epileptic Encephalopathy 1active not recruiting160
2026-12 est.P3Praxis Precision Medicines PRAXNCT07019922 A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and SafetyEpileptic Encephalopathy; SCN2A Encephalopathyrecruiting40
2026-12-30 est.P1/P2Supernus Pharmaceuticals, Inc. SUPNNCT03474770 BIS-001-ER for the Treatment of Adult Focal Impaired Awareness SeizuresFocal Impaired Awareness Seizuresactive not recruiting16
2026-12-31 est.P3Longboard PharmaceuticalsNCT06660394 A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)Dravet Syndromeactive not recruiting108
2027-01 est.P3Praxis Precision Medicines PRAXNCT07505004 Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal SeizuresFocal Epilepsyactive not recruiting300
2027-01 est.P2Actio Biosciences, Inc.NCT07600736 A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-relateKCNT1-Related Epilepsyrecruiting61
2027-01-31 est.P3Ono Pharmaceutical Co., Ltd.NCT06579573 ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.Epilepsy, Generalizedrecruiting15
2027-01-31 est.P2Ono Pharmaceutical Co., Ltd.NCT06590896 Safety of Cenobamate in Japanese Subjects With Partial Onset SeizuresEpilepsies, Partialrecruiting100
2027-02 est.P3SK Life Science, Inc.NCT05219617 Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and AdultsSeizures; Lennox Gastaut Syndromerecruiting252

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-01 est.P3EpygenixNCT05066217 An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut SyndromeLennox Gastaut Syndromerecruiting260
2026-10-31 est.P3Longboard PharmaceuticalsNCT06719141 A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)Developmental and Epileptic Encephalopathyactive not recruiting367
2026-10-02P3SK Life Science, Inc.NCT05067634 Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) SeizuresPartial Epilepsycompleted154
2026-10 est.P2/P3Biohaven Therapeutics Ltd. BHVNNCT06309966 Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyFocal Epilepsyactive not recruiting390
2026-09-01P3UCB BIOSCIENCES, Inc.NCT06118255 A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet SyndromDravet Syndromecompleted25
2026-08-17P2NeuroPro Therapeutics, Inc.NCT06769659 A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence SeizuresEpilepsy, Generalized; Epilepsy, Absencecompleted14
2026-07-07P3UCB Biopharma SRLNCT04666610 A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or JuChildhood Absence Epilepsy; Juvenile Absence Epilepsycompleted154
2026-06-10P3SK Life Science, Inc.NCT03961568 Cenobamate Open-Label Extension Study for YKP3089C025Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsycompleted147

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "epilepsy"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.